Company intelligence / Profile preview

Cellexus

Dundee, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

The CellMaker single-use airlift bioreactor systems are commercially available and demonstrate proven performance in production of bacteriophage, E. coli-derived proteins, mammalian cell culturing, antibody, and phage production, with documented efficiency and reduced contamination risk

Modalities: DeviceBioprocess equipment (single-use airlift bioreactor systems for production of microbial, mammalian, plant, and phage-derived biologics)
Industry: Non-Drug Biotech

Partnerships

2BScientific (invested, partnership for distribution)Green Bioactives Ltd (user/testimonial, plant cell culture platform)Fixed Phage (user/testimonial, upscaling phage production)

Beyond the preview

Go deeper on Cellexus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellexus.

Explore the full profile